These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 17514743

  • 1. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
    Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE.
    Cancer; 2007 Jun 01; 109(11):2291-8. PubMed ID: 17514743
    [Abstract] [Full Text] [Related]

  • 2. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A.
    J Clin Oncol; 2009 Feb 01; 27(4):498-503. PubMed ID: 19075274
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
    Weiss MA.
    Semin Oncol; 2000 Apr 01; 27(2 Suppl 5):41-3. PubMed ID: 10877051
    [Abstract] [Full Text] [Related]

  • 6. An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
    Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L.
    Cancer; 2005 Mar 01; 103(5):978-84. PubMed ID: 15672388
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Błoński JZ.
    Eur J Haematol; 2007 Aug 01; 79(2):107-13. PubMed ID: 17635235
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF.
    Cancer; 2004 May 15; 100(10):2181-9. PubMed ID: 15139062
    [Abstract] [Full Text] [Related]

  • 13. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD.
    Clin Lymphoma Myeloma; 2005 Sep 15; 6(2):131-5. PubMed ID: 16231851
    [Abstract] [Full Text] [Related]

  • 14. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T, Blonski JZ, Wawrzyniak E, Gora-Tybor J, Palacz A, Dmoszynska A, Konopka L, Warzocha K, Jamroziak K.
    Cancer; 2009 Jan 01; 115(1):94-100. PubMed ID: 19025975
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 16. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS.
    Cancer; 2013 Nov 01; 119(21):3788-96. PubMed ID: 23922059
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.